https://yoda.yale.edu/clinical-trial/nct02264574-a-randomized-multi-center-open-label-phase-3-study-of-the-brutons-tyrosine-kinase-inhibitor-ibrutinib-in-combination-with-obinutuzumab-versus-chlorambucil-in-combination-with-obinutu/
NCT02264574 - A Randomized, Multi-center, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase...